Phosphodiesterase 3 Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the phosphodiesterase 3 inhibitor [epc] class. 5 active patents protecting 1 drugs. First major cliff: 2031. Daily refresh.

1
Drugs in class
5
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators

Verona Pharma 5 patents

Cliff calendar — next 15 years

1
31
2
35

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ohtuvayre
ENSIFENTRINE
 Verona Pharma 5 64 — 2031-08-21

Most attackable patents

Patent Drug Type Vuln Expiry
9062047 Ohtuvayre method of use 81 2031-08-21
9956171 Ohtuvayre method of use 75 2035-09-15
10945950 Ohtuvayre formulation 55 2035-09-15
12409180 Ohtuvayre formulation 55 2043-02-20
12251384 Ohtuvayre formulation 55 2044-06-25

Strongest defences

Patent Drug Type Vuln Expiry
12251384 Ohtuvayre formulation 55 2044-06-25
12409180 Ohtuvayre formulation 55 2043-02-20
10945950 Ohtuvayre formulation 55 2035-09-15
9956171 Ohtuvayre method of use 75 2035-09-15
9062047 Ohtuvayre method of use 81 2031-08-21

Related